Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlind Mücke

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|February 8, 2002
Asymmetric photocross-linking pattern of restriction endonuclease EcoRII to the DNA recognition sequenceMerlind Mücke, Vera Pingoud, Gerlinde Grelle, et al.
The EMBO Journal|October 3, 2002
EcoRII: a restriction enzyme evolving recombination functions?Merlind Mücke, Gerlinde Grelle, Joachim Behlke, et al.
Nucleic Acids Research|August 15, 2002
Counting CAG repeats in the Huntington's disease gene by restriction endonuclease EcoP15I cleavageElisabeth Möncke-Buchner, Stefanie Reich, Merlind Mücke, et al.
Journal of Molecular Biology|December 9, 2003
Crystal structure of type IIE restriction endonuclease EcoRII reveals an autoinhibition mechanism by a novel effector-binding foldXiaoyin E Zhou, Yujun Wang, Monika Reuter, et al.
Cancer Research Communications|June 12, 2026
Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor controlPatrick A A Weber, Mario Perro, Valeria G Nicolini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|February 8, 2002
Asymmetric photocross-linking pattern of restriction endonuclease EcoRII to the DNA recognition sequenceMerlind Mücke, Vera Pingoud, Gerlinde Grelle, et al.
The EMBO Journal|October 3, 2002
EcoRII: a restriction enzyme evolving recombination functions?Merlind Mücke, Gerlinde Grelle, Joachim Behlke, et al.
Nucleic Acids Research|August 15, 2002
Counting CAG repeats in the Huntington's disease gene by restriction endonuclease EcoP15I cleavageElisabeth Möncke-Buchner, Stefanie Reich, Merlind Mücke, et al.
Journal of Molecular Biology|December 9, 2003
Crystal structure of type IIE restriction endonuclease EcoRII reveals an autoinhibition mechanism by a novel effector-binding foldXiaoyin E Zhou, Yujun Wang, Monika Reuter, et al.
Cancer Research Communications|June 12, 2026
Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor controlPatrick A A Weber, Mario Perro, Valeria G Nicolini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Pageof 1